Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

F0250000

Fluorouracil

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

5-Fluorouracil, 2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C4H3FN2O2
Numero CAS:
51-21-8
Peso molecolare:
130.08
Beilstein:
127172
Numero MDL:
MFCD00006018
Codice UNSPSC:
41116107
ID PubChem:
329799645
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

fluorouracil

Produttore/marchio commerciale

EDQM

Punto di fusione

282-286 °C (dec.) (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
GHASVSINZRGABV-UHFFFAOYSA-N

Informazioni sul gene

human ... TYMS(7298)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Fluorouracil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0000762

Fluorouracil impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000763

Fluorouracil impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000791

Fluorouracil impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0000765

Fluorouracil impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000764

Fluorouracil impurity C, European Pharmacopoeia (EP) Reference Standard

1279000

Fluorouracil, United States Pharmacopeia (USP) Reference Standard

1279054

Fluorouracil Related Compound E, United States Pharmacopeia (USP) Reference Standard

1279065

Fluorouracil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1279019

Fluorouracil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1279021

Fluorouracil Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

Fluorouracil Related Compound A, certified reference material, pharmaceutical secondary standard

PHR2866

Fluorouracil Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2867

Fluorouracil Related Compound E, certified reference material, pharmaceutical secondary standard

PHR2868

Fluorouracil Related Compound F, certified reference material, pharmaceutical secondary standard

Pittogrammi

Skull and crossbonesHealth hazard
GHS06,GHS08

Avvertenze

Danger

Indicazioni di pericolo

H301,H351

Classi di pericolo

Acute Tox. 3 Oral - Carc. 2

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Fluorouracil impurity C European Pharmacopoeia (EP) Reference Standard

Y0000764

Fluorouracil impurity C

Gemcitabine hydrochloride European Pharmacopoeia (EP) Reference Standard

Y0000675

Gemcitabine hydrochloride

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

5-Fluorouracil for synthesis

Sigma-Aldrich

8.18505

5-Fluorouracil

5-Fluorouracil Potent antitumor agent.

Sigma-Aldrich

343922

5-Fluorouracil

Oxaliplatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1528

Oxaliplatin

7-Ethyl-10-hydroxycamptothecin ≥98% (HPLC), powder

Sigma-Aldrich

H0165

7-Ethyl-10-hydroxycamptothecin

André Bp van Kuilenburg et al.
Pharmacogenomics, 14(7), 799-811 (2013-05-09)
5-fluorouracil (5-FU) remains the cornerstone of all currently applied regimens for the treatment of patients with cancers of the gastrointestinal tract, breast, and head and neck. Unfortunately, a large variation in the clearance of 5-FU has been observed between patients
Larissa S Carnevalli et al.
The Journal of experimental medicine, 211(5), 769-779 (2014-04-23)
The serine protease granzyme B (GzmB) is stored in the granules of cytotoxic T and NK cells and facilitates immune-mediated destruction of virus-infected cells. In this study, we use genetic tools to report novel roles for GzmB as an important
Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
Anne Polk et al.
Cancer treatment reviews, 39(8), 974-984 (2013-04-16)
To systematically review the incidence, manifestations and predisposing factors for cardiovascular toxicity in cancer patients treated with systemic 5-fluorouracil or capecitabine. We searched PubMed, EMBASE and Web of science for studies with ≥ 20 cancer patients evaluating cardiovascular toxicity of
Guido Deboever et al.
Clinical colorectal cancer, 12(1), 8-14 (2012-10-30)
Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.